Collaborators and partners

The types of problems underlying unmet medical needs and sustainability issues often require a collaborative approach.

We partner with biochemists, structural biologists and clinicians to facilitate our research programmes and drive our technologies to market.

Our key collaborators include:

• Professor Vern Schramm, Albert Einstein College of Medicine
• Professor Jerry Turnbull, University of Liverpool
• Professor John Miller, Victoria University of Wellington
• Professor Ian Hermans, Malaghan Institute of Medical Research
• Professor Simon Cool, Agency for Science, Technology and Research, Singapore

Avalia Immunotherapies

Avalia Immunotherapies is a preclinical stage biotech company that has licensed a powerful, fully synthetic vaccine and immunotherapy platform from Ferrier Research Institute and Malaghan Institute of Medical Research.

The technology platform has the ability to influence a special family of immune cells known as natural killer T (NKT) cells, which can play a key role in treating and preventing infectious disease and cancer. Avalia's lead program is targeting a cure for the >250 million sufferers of chronic hepatitis B (>90 million in China alone).

There is currently no cure available and 25% of patients progress to life threatening liver disease (cirrhosis, hepatocellular carcinoma), with 1 million annual deaths worldwide. Avalia’s therapy activates our immune system’s first responders, NKT cells, which have the ability to generate a powerful response in the liver, the site of hepatitis infection.

Glycosyn

When a project is ready to move beyond laboratory scale, we work alongside experts in process chemistry and chemical engineering at GlycoSyn—our on-site cGMP (current good manufacturing practice) joint venture partner. GlycoSyn specialises in developing the manufacturing methods necessary to make materials in sufficient quantity and quality for clinical trials. We work together closely to offer a seamless service for clients.